VERU Veru Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

VERU [NASD]

Veru Inc.

Healthcare | Drug Manufacturers - Specialty & Generic | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.15	Insider Own	1.30%	Shs Outstand	65.37M	Perf Week	-4.49%
Market Cap	216.66M	Forward P/E	-	EPS next Y	-0.05	Insider Trans	0.80%	Shs Float	50.21M	Perf Month	-5.90%
Income	-10.00M	PEG	-	EPS next Q	-0.03	Inst Own	16.30%	Short Float	0.61%	Perf Quarter	4.93%
Sales	39.00M	P/S	5.56	EPS this Y	57.30%	Inst Trans	22.85%	Short Ratio	0.51	Perf Half Y	-12.36%
Book/sh	0.48	P/B	6.65	EPS next Y	61.50%	ROA	-18.30%	Target Price	-	Perf Year	41.15%
Cash/sh	0.04	P/C	83.33	EPS next 5Y	-	ROE	-31.10%	52W Range	1.67 - 4.74	Perf YTD	-4.78%
Dividend	-	P/FCF	-	EPS past 5Y	-33.60%	ROI	-13.80%	52W High	-32.70%	Beta	0.39
Dividend %	-	Quick Ratio	0.70	Sales past 5Y	5.40%	Gross Margin	69.60%	52W Low	91.02%	ATR	0.24
Employees	386	Current Ratio	1.00	Sales Q/Q	41.40%	Oper. Margin	-14.00%	RSI (14)	42.31	Volatility	4.76% 7.52%
Optionable	Yes	Debt/Eq	0.43	EPS Q/Q	80.70%	Profit Margin	-25.50%	Rel Volume	0.86	Prev Close	3.19
Shortable	Yes	LT Debt/Eq	0.22	Earnings	May 13 BMO	Payout	-	Avg Volume	601.97K	Price	3.19
Recom	1.70	SMA20	-4.87%	SMA50	-9.21%	SMA200	2.86%	Volume	515,276	Change	0.00%

Jan-21-20

Reiterated

H.C. Wainwright

Buy

$4.50 → $6

Mar-20-19

Initiated

Oppenheimer

Outperform

Jul-03-18

Initiated

Maxim Group

Buy

Jul-06-20 09:45AM	Do Options Traders Know Something About Veru (VERU) Stock We Don't? Zacks
Jun-29-20 08:30AM	Veru Inc. Added to the Russell 2000 and 3000 Indices GlobeNewswire +6.85%
Jun-25-20 08:44AM	Veru (VERU) Soars: Stock Adds 6.9% in Session Zacks
Jun-23-20 09:11PM	Hedge Funds Keep Buying Veru Inc. (VERU) Insider Monkey -7.00%
Jun-19-20 08:30AM	Veru Enrolls First Patient in Phase 2 Clinical Trial of Novel Drug, VERU-111, to Combat COVID-19 GlobeNewswire +6.13%
Jun-12-20 09:45AM	3 Strong Buy Penny Stocks With Massive Upside Ahead TipRanks
May-26-20 08:30AM	Veru to Present at Jefferies Virtual Healthcare Conference on June 2nd GlobeNewswire
May-15-20 12:39PM	Veru Inc. (NASDAQ:VERU) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? Simply Wall St.
May-13-20 03:30PM	Veru Inc. (VERU) Q2 2020 Earnings Call Transcript Motley Fool +12.46%
11:48AM	Why Veru Stock Is Vaulting Higher Today Motley Fool
06:58AM	Recap: Veru Q2 Earnings Benzinga
06:30AM	Veru Reports Strong Fiscal 2020 Second Quarter Results as Net Revenues Increase 43%, Gross Profit Up 61% GlobeNewswire
May-12-20 12:00PM	Veru Secures FDA Agreement to Initiate Phase 2 Study of VERU-111, Novel Microtubule Depolymerization Drug to Combat COVID-19 GlobeNewswire -6.12%
May-06-20 08:30AM	Veru to Report Fiscal 2020 Second-Quarter Financial Results, Host Conference Call on May 13th GlobeNewswire
May-05-20 08:30AM	Veru Reports Positive Clinical Results from VERU-111 Phase 1b/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer, Advancing to Pivotal Phase 3 Clinical Program GlobeNewswire +16.07%
Feb-26-20 08:30AM	Veru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug GlobeNewswire
Feb-12-20 06:30AM	Veru Continues Strong Positive Sales Momentum in Fiscal 2020 First Quarter; Net Revenues Increase 66%, Gross Profit Up 57% GlobeNewswire
Feb-05-20 08:30AM	Veru to Report Fiscal 2020 First-Quarter Financial Results, Host Conference Call on February 12th GlobeNewswire
Jan-30-20 11:40AM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Veru Inc. - VERU ACCESSWIRE
Jan-29-20 07:01AM	Top Ranked Momentum Stocks to Buy for January 29th Zacks +5.71%
Jan-21-20 08:30AM	Veru Announces Acceptance of Two Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2020 GlobeNewswire +8.83%
Jan-14-20 07:55AM	The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug Benzinga
Jan-13-20 08:00AM	Veru Announces Positive Top-Line Interim Data from Phase 2 Clinical Trial of Zuclomiphene to Treat Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy GlobeNewswire
Jan-09-20 08:56AM	3 Healthcare Stocks With Big Catalysts in January TipRanks +8.06%
07:07AM	Will Veru Continue to Surge Higher? Zacks
Dec-23-19 06:24PM	Hedge Funds Have Never Been This Bullish On Veru Inc. (VERU) Insider Monkey
Dec-17-19 07:09AM	Will Veru Continue to Surge Higher? Zacks
Dec-16-19 10:37AM	US$7.38 - That's What Analysts Think Veru Inc. Is Worth After These Results Simply Wall St. +14.11%
Dec-12-19 06:30AM	Veru Reports Fiscal 2019 Full-Year Net Revenues Doubled, Gross Profit Up 147% GlobeNewswire
Dec-05-19 08:30AM	Veru to Report Fiscal 2019 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 12th GlobeNewswire
Oct-10-19 01:43PM	Veru (NASDAQ:VERU) Shareholders Have Enjoyed A 93% Share Price Gain Simply Wall St.
Oct-02-19 06:30AM	Veru Announces Full Enrollment of Phase 2 Trial in Men with Prostate Cancer Treatment Induced Hot Flashes GlobeNewswire
Sep-04-19 10:53AM	Does Veru (NASDAQ:VERU) Have A Healthy Balance Sheet? Simply Wall St.
Aug-28-19 08:30AM	Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York GlobeNewswire +6.63%
Aug-27-19 08:30AM	Veru to Ring NASDAQ Closing Bell on September 4th to Kick Off National Prostate Cancer Awareness Month GlobeNewswire -9.05%
Aug-08-19 06:30AM	Veru Reports Higher Net Revenues and Gross Profit for its Fiscal 2019 Third Quarter GlobeNewswire -7.02%
Aug-01-19 09:19PM	Veru to Report Fiscal 2019 Third-Quarter Financial Results; Host Conference Call on August 8th GlobeNewswire
Jul-31-19 01:50PM	Biotech Stock On The Radar: Veru, A Catalyst-Rich Biopharma Benzinga
Jul-26-19 03:06PM	What Kind Of Shareholder Appears On The Veru Inc.'s (NASDAQ:VERU) Shareholder Register? Simply Wall St. +6.54%
Jul-18-19 02:07PM	Veru Announces Dismissal of Lawsuit; Prevails on All Counts in Motion for Summary Judgment GlobeNewswire
Jul-08-19 09:32AM	Options Traders Expect Huge Moves in Veru (VERU) Stock Zacks
Jun-26-19 08:30AM	Veru Announces Successful Completion of Pre-NDA Meeting with FDA for TADFIN (Tadalafil 5mg and Finasteride 5mg) Combination for the Treatment of Benign Prostatic Hyperplasia GlobeNewswire
Jun-04-19 08:00AM	Veru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA GlobeNewswire +11.30%
May-28-19 08:30AM	Veru to Present at the Jefferies 2019 Global Healthcare Conference on June 4th GlobeNewswire
May-24-19 01:19PM	Is Veru Inc.'s (NASDAQ:VERU) CEO Overpaid Relative To Its Peers? Simply Wall St.
May-15-19 06:30AM	Veru Reports Strong Fiscal 2019 Second-Quarter Financial Results GlobeNewswire -5.95%
May-08-19 08:30AM	Veru to Report Fiscal 2019 Second-Quarter Financial Results; Host Conference Call on May 15th GlobeNewswire
May-06-19 07:02AM	Veru: This is a market correction you're going to want to buy CNBC Videos
May-01-19 10:33AM	Veru (VERU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Apr-05-19 02:47PM	Introducing Veru (NASDAQ:VERU), The Stock That Tanked 81% Simply Wall St.
Mar-12-19 08:00AM	Veru to Participate in Two Investor Conferences in March GlobeNewswire
Mar-06-19 01:23PM	Have Insiders Been Buying Veru Inc. (NASDAQ:VERU) Shares This Year? Simply Wall St.
Feb-13-19 06:30AM	Veru Reports Strong Fiscal 2019 First Quarter Financial Results GlobeNewswire -8.72%
Feb-12-19 08:00AM	Veru Announces Scientific Presentations for Novel Prostate Cancer Drug Candidates at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium GlobeNewswire
Feb-06-19 10:31AM	Earnings Preview: Veru (VERU) Q1 Earnings Expected to Decline Zacks -5.19%
08:30AM	Veru to Report Fiscal 2019 First-Quarter Financial Results, Host Conference Call on February 13th GlobeNewswire
Jan-22-19 08:30AM	Veru Initiates Clinical Trial for Proprietary, Novel, First-in-Class Drug for Advanced Prostate Cancer GlobeNewswire
Jan-18-19 08:26AM	Before You Buy Veru Inc. (NASDAQ:VERU), Consider Its Volatility Simply Wall St.
Jan-15-19 08:00AM	Veru Announces Acceptance of Four Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2019 GlobeNewswire
Jan-14-19 08:00AM	Veru Announces Successful Bioavailability and Bioequivalence Clinical Trial for Tadalafil and Finasteride Combination Tablet for Benign Prostatic Hyperplasia GlobeNewswire
Dec-13-18 06:30AM	Veru Reports Strong Net Revenues and Gross Profit for Fiscal 2018 Fourth-Quarter GlobeNewswire
Dec-06-18 08:30AM	Veru to Report Fiscal Year 2018 Financial Results, Host Conference Call on December 13th GlobeNewswire
Dec-03-18 02:33PM	What Kind Of Shareholders Own Veru Inc (NASDAQ:VERU)? Simply Wall St.
08:30AM	Veru Announces First Patient Dosed in Bioequivalence Clinical Trial for Combination Tadalafil Finasteride Tablet for Benign Prostatic Hyperplasia GlobeNewswire
Nov-13-18 08:30AM	Veru Advances Novel, First-in-Class Oral Tubulin Inhibitor for Refractory Metastatic Prostate Cancer GlobeNewswire
Oct-01-18 07:30AM	First Patient Enrolled in Phase 2 Study of Zuclomiphene Citrate for Treatment of Hot Flashes Caused by Androgen Deprivation Therapy GlobeNewswire -7.75%
Sep-27-18 05:00PM	Veru to Present at Upcoming Healthcare Investor Conferences in New York GlobeNewswire -18.82%
09:05AM	Veru Announces Pricing of Public Offering of Common Stock GlobeNewswire
Sep-26-18 04:01PM	Veru Announces Proposed Public Offering of Common Stock GlobeNewswire -5.03%
Sep-12-18 08:00AM	Veru has Successful Pre-IND Meeting with FDA for VERU-111 Next Generation Novel Oral Anti-Tubulin Therapy for Metastatic Prostate Cancer GlobeNewswire
Aug-30-18 08:00AM	Veru to Ring NASDAQ Closing Bell on August 31 to Kick Off National Prostate Cancer Awareness Month GlobeNewswire
Aug-29-18 08:00AM	Veru Announces Additional Information Regarding its South Africa Female Condom Tender Award GlobeNewswire
Aug-28-18 08:00AM	South Africa Female Condom Tender Award Additional Information GlobeNewswire
Aug-27-18 08:00AM	Veru Awarded 75 Percent of South Africa Female Condom Tender GlobeNewswire
Aug-14-18 06:30AM	Veru Reports Fiscal 2018 Third Quarter Financial Results GlobeNewswire
06:00AM	Veru Inc to Host Earnings Call ACCESSWIRE
Aug-07-18 04:08PM	Veru to Report Fiscal 2018 Third-Quarter Financial Results, Host Conference Call on August 14th GlobeNewswire +12.56%
Jun-12-18 08:30AM	Veru to Start Phase 2 Trial to Evaluate Cis-Clomiphene Citrate to Treat Hot Flashes Caused by Advanced Prostate Cancer Therapy GlobeNewswire +9.63%
May-30-18 08:30AM	Veru to Present at Jefferies 2018 Global Healthcare Conference on Wednesday, June 6th GlobeNewswire
May-17-18 08:30AM	Veru Announces Publication of Data from Three Cancer Studies as Part of the Upcoming American Society of Clinical Oncology Annual Meeting GlobeNewswire
08:15AM	Veru Announces Publication of Data on Oral VERU-111 in Prostate Cancer in Connection with the 2018 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-09-18 06:30AM	Veru Reports Fiscal 2018 Second-Quarter Financial Results GlobeNewswire -9.63%
May-03-18 08:40AM	Veru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model at the 2018 American Urological Association Meeting GlobeNewswire
08:30AM	Veru to Report Fiscal 2018 Second-Quarter Financial Results, Host Conference Call on May 9th GlobeNewswire
Mar-22-18 08:30AM	FDA Grants Fee Waiver for Tamsulosin DRS New Drug Application GlobeNewswire
Mar-16-18 08:30AM	Veru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model at the 2018 Annual EAU Congress GlobeNewswire
Mar-14-18 08:30AM	Veru to Present at the Oppenheimer 28th Annual Healthcare Conference on March 21, 2018 GlobeNewswire
Mar-05-18 08:30AM	Veru Completes $10 Million Synthetic Royalty Financing on FC2 Business GlobeNewswire
Feb-14-18 06:30AM	Veru Reports Fiscal 2018 First-Quarter Financial Results GlobeNewswire
06:00AM	Veru Inc to Host Earnings Call ACCESSWIRE
Feb-07-18 08:30AM	Veru to Report Fiscal 2018 First-Quarter Financial Results, Host Conference Call on February 14 GlobeNewswire
Feb-06-18 08:30AM	Veru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model at the 2018 Genitourinary Cancers Symposium GlobeNewswire +5.34%
Jan-16-18 07:30AM	Free Research Report as Verus Revenue Grew 3.6% ACCESSWIRE
Jan-02-18 07:00AM	Veru Reports Fiscal 2017 Fourth-Quarter, Full-Year Financial Results GlobeNewswire +25.44%
Dec-14-17 02:15PM	ETFs with exposure to Veru, Inc. : December 14, 2017 Capital Cube -13.48%
Dec-11-17 08:30AM	Veru Acquires Novel Proprietary Formulation for Overactive Bladder GlobeNewswire
Nov-21-17 05:59PM	At $1.1572, Is Veru Inc (VERU) A Buy? Simply Wall St.
Nov-13-17 08:30AM	Veru Announces Tamsulosin DRS Bioequivalence Clinical Trial Results GlobeNewswire
Oct-03-17 08:30AM	Veru Inc. Announces Agreement with Timm Medical Technologies, LLC to Distribute and to Promote PREBOOST GlobeNewswire -10.57%
Sep-28-17 10:21AM	ETFs with exposure to Veru, Inc. : September 28, 2017 Capital Cube -6.34%

Veru Inc., an oncology and urology biopharmaceutical company, engages in developing novel medicines for prostate cancer treatment and prostate cancer supportive care. The company's oncology drug candidates include VERU-111, an oral alpha and beta tubulin inhibitor, which is in a development Phase 1b/2 for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a Phase 2 clinical trial for the treatment of hot flashes in men undergoing androgen deprivation therapies; and VERU-100, a GnRH antagonist that is in planned Phase 2 clinical trial for the palliative treatment of advanced prostate cancer. Its urology specialty drug candidates are TADFIN, a tadalafil and finasteride combination of tablets and capsules for the treatment of men with lower urinary tract symptoms; and Tamsulosin XR capsules, which are tamsulosin capsules for treating benign prostatic hyperplasia. The company's commercial products include the FC2 Female/Internal condoms for the prevention of pregnancy and sexually transmitted infections; and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation. Its customers primarily include international agencies, government health agencies, ministries of health, and other governmental agencies, which purchase and distribute FC2 for use in HIV/AIDS prevention and family planning programs; and telemedicine providers who sell into the prescription channel in the United States. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FISCH HARRY	Director	Feb 21	Buy	4.47	1,000	4,470	859,025	Feb 24 12:31 PM
FISCH HARRY	Director	Feb 20	Buy	4.51	1,000	4,510	858,025	Feb 21 11:44 AM
Socorro Jesus	Director	Feb 19	Buy	4.27	5,000	21,350	32,500	Feb 19 05:30 PM
Socorro Jesus	Director	Dec 19	Buy	2.80	5,000	14,000	27,500	Dec 20 12:53 PM
STEINER MITCHELL SHUSTER	President and CEO	Dec 05	Sale	2.22	16,590	36,846	7,434,767	Dec 06 11:53 AM
STEINER MITCHELL SHUSTER	President and CEO	Dec 04	Sale	2.20	8,410	18,494	7,451,357	Dec 06 11:53 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience